JP2022535708A5 - - Google Patents
Info
- Publication number
- JP2022535708A5 JP2022535708A5 JP2021569341A JP2021569341A JP2022535708A5 JP 2022535708 A5 JP2022535708 A5 JP 2022535708A5 JP 2021569341 A JP2021569341 A JP 2021569341A JP 2021569341 A JP2021569341 A JP 2021569341A JP 2022535708 A5 JP2022535708 A5 JP 2022535708A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- nucleotides
- group
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024223651A JP2025041739A (ja) | 2019-05-24 | 2024-12-19 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910440575 | 2019-05-24 | ||
| CN201910440575.8 | 2019-05-24 | ||
| PCT/CN2020/091624 WO2020238763A1 (zh) | 2019-05-24 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024223651A Division JP2025041739A (ja) | 2019-05-24 | 2024-12-19 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535708A JP2022535708A (ja) | 2022-08-10 |
| JP2022535708A5 true JP2022535708A5 (enExample) | 2023-05-29 |
| JP7613751B2 JP7613751B2 (ja) | 2025-01-15 |
Family
ID=73553779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569341A Active JP7613751B2 (ja) | 2019-05-24 | 2020-05-21 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| JP2024223651A Pending JP2025041739A (ja) | 2019-05-24 | 2024-12-19 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024223651A Pending JP2025041739A (ja) | 2019-05-24 | 2024-12-19 | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220186221A1 (enExample) |
| EP (1) | EP3978029A4 (enExample) |
| JP (2) | JP7613751B2 (enExample) |
| KR (1) | KR20220012284A (enExample) |
| CN (2) | CN113795280B (enExample) |
| AU (1) | AU2020282453A1 (enExample) |
| CA (1) | CA3140233A1 (enExample) |
| WO (1) | WO2020238763A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| DK3719128T3 (da) | 2017-12-01 | 2025-03-03 | Suzhou Ribo Life Science Co Ltd | Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf |
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| KR20220011689A (ko) * | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN115028670B (zh) * | 2022-06-24 | 2023-07-28 | 四川大学华西医院 | 一种n-乙酰基-d-半乳糖胺三聚体前体的制备方法 |
| WO2024255747A1 (zh) * | 2023-06-16 | 2024-12-19 | 施能康医药科技(苏州)有限公司 | 靶向补体成分5的核酸及其用途 |
| WO2025026124A1 (zh) * | 2023-08-03 | 2025-02-06 | 苏州炫景生物科技有限公司 | C4b基因抑制剂组合物及其应用 |
| CN119585432B (zh) * | 2023-08-22 | 2025-08-12 | 成都先衍生物技术有限公司 | 一种靶向AGT基因表达的siRNA及其缀合物和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| IL288931B2 (en) * | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| CA2950960A1 (en) * | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| US10036017B2 (en) * | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
| WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| CN110944675B9 (zh) * | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CA3083970A1 (en) * | 2017-12-01 | 2019-06-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| AU2018394875B2 (en) * | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| KR20220011689A (ko) * | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
-
2020
- 2020-05-21 CN CN202080033909.0A patent/CN113795280B/zh active Active
- 2020-05-21 WO PCT/CN2020/091624 patent/WO2020238763A1/zh not_active Ceased
- 2020-05-21 US US17/595,577 patent/US20220186221A1/en active Pending
- 2020-05-21 EP EP20814338.8A patent/EP3978029A4/en active Pending
- 2020-05-21 CA CA3140233A patent/CA3140233A1/en active Pending
- 2020-05-21 KR KR1020217041240A patent/KR20220012284A/ko active Pending
- 2020-05-21 CN CN202410300945.9A patent/CN118217305A/zh active Pending
- 2020-05-21 JP JP2021569341A patent/JP7613751B2/ja active Active
- 2020-05-21 AU AU2020282453A patent/AU2020282453A1/en active Pending
-
2024
- 2024-12-19 JP JP2024223651A patent/JP2025041739A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535708A5 (enExample) | ||
| JP2022533841A5 (enExample) | ||
| JP2021503940A5 (enExample) | ||
| JP2021503929A5 (enExample) | ||
| JP2022533722A5 (enExample) | ||
| JP2022501059A5 (enExample) | ||
| JP2021503930A5 (enExample) | ||
| HRP20250192T1 (hr) | Nukleinska kiselina, sastav i konjugat koji je sadrži, te metoda pripreme i uporaba | |
| JP2022534069A5 (enExample) | ||
| CN113795280A (zh) | 核酸、药物组合物与缀合物及制备方法和用途 | |
| JP2021503941A5 (enExample) | ||
| JP2022533419A5 (enExample) | ||
| JP2021533800A5 (enExample) | ||
| JP2022534702A5 (enExample) | ||
| JP7684373B2 (ja) | オフターゲット効果が低下した修飾ｒｎａ剤 | |
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| JP2022533421A5 (enExample) | ||
| US20210017214A1 (en) | Galnac phosphoramidites, nucleic acid conjugates thereof and their use | |
| JP6985288B2 (ja) | トリチル−モノ−ＧａｌＮＡｃ化合物とその利用 | |
| CN105164261B (zh) | 用于增强的细胞摄取的化合物和方法 | |
| JP2023536320A5 (enExample) | ||
| JP2022528840A5 (enExample) | ||
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2022546055A5 (enExample) | ||
| CN111465694A (zh) | 用于抑制细胞中lpa的表达的核酸 |